Renin-angiotensin-aldosterone System Blockers, Hypertension, and Clinical Outcomes

@inproceedings{Babu2018ReninangiotensinaldosteroneSB,
  title={Renin-angiotensin-aldosterone System Blockers, Hypertension, and Clinical Outcomes},
  author={S. K. Babu and R. Augustine},
  year={2018}
}
Our knowledge of the RAAS started in 1898 when Tigerstedt and Bergman showed that renal extract from rabbits increased BP when infused and named it as renin.[1] In 1934, Goldblatt demonstrated that renal artery constriction caused renal ischemia and induced hypertension (HTN) in dogs. Later, in 1939–1940, Braun-Menende in Argentina and Page and Helmer in the USA simultaneously discovered a pressor substance capable of causing renal HTN. This was originally named hypertensin in Argentina and… Expand

References

SHOWING 1-10 OF 15 REFERENCES
RAAS inhibition and mortality in hypertension
  • R. Ferrari
  • Medicine
  • Global cardiology science & practice
  • 2013
TLDR
The differences between RAAS inhibitors in terms of pharmacological and clinical effects are considered and the impact of the main types of RAAS inhibitor, ACE inhibitors and ARBs, on mortality reduction in hypertensive patients is analyzed with reference to this latest meta-analysis. Expand
Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
TLDR
This review will examine new anti-hypertensive medications affecting the RAAS, evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice. Expand
The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
  • S. Atlas
  • Medicine
  • Journal of managed care pharmacy : JMCP
  • 2007
TLDR
Therapeutic approaches that target more complete inhibition of the RAAS may offer additional clinical benefits for patients with cardiovascular and renal disorders and new therapeutic modalities such as direct renin inhibition with aliskiren, recently approved for the treatment of hypertension. Expand
Drug discovery in renin–angiotensin system intervention: past and future
  • B. Williams
  • Medicine
  • Therapeutic advances in cardiovascular disease
  • 2016
TLDR
While the RAS is far more complex than originally thought, much is now known about this system and the wide ranging effects of angiotensin in the body that has enabled the development of therapies that target the various proteins in this pathway and hence are implicated in disease. Expand
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
TLDR
The recent introduction of the direct renin inhibitor, aliskiren, has made available new combination strategies to obtain a more complete blockade of the RAAS with fewer adverse events. Expand
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients
TLDR
In patients with hypertension, treatment with an ACE inhibitor results in a significant further reduction in all-cause mortality, and the widespread use of ACE inhibitors may result in an important gain in lives saved. Expand
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
TLDR
Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes and early nephropathy, and these findings support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in people with conditions that place them at high risk for cardiovascular events. Expand
Direct renin inhibition: focus on aliskiren.
  • J. Pool
  • Medicine
  • Journal of managed care pharmacy : JMCP
  • 2007
TLDR
When used once daily, aliskiren is a safe and effective antihypertensive agent that can be used as monotherapy or in combination with other agents to provide additional options to improve BP control. Expand
Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial
TLDR
A combination of ACEi and ARB does not increase strokes or alter other major cardiovascular or renal events in patients with diabetes, irrespective of the presence of nephropathy. Expand
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
TLDR
Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy and safety outcomes included mortality, hyperkalemia, and acute kidney injury. Expand
...
1
2
...